The National Comprehensive Cancer Network's (NCCN) guidelines regarding cancer risk and management for the CHEK2 gene are based on frameshift mutations (Daly et al., 2018; Provenzale et al., 2017). This evidence concerns the gene CHEK2 and cancer.